PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
TAK vs. XLI
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between TAK and XLI is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.3

Performance

TAK vs. XLI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Takeda Pharmaceutical Company Limited (TAK) and Industrial Select Sector SPDR Fund (XLI). The values are adjusted to include any dividend payments, if applicable.

-10.00%-5.00%0.00%5.00%10.00%SeptemberOctoberNovemberDecember2025February
-4.43%
9.23%
TAK
XLI

Key characteristics

Sharpe Ratio

TAK:

-0.07

XLI:

1.49

Sortino Ratio

TAK:

0.02

XLI:

2.21

Omega Ratio

TAK:

1.00

XLI:

1.26

Calmar Ratio

TAK:

-0.03

XLI:

2.44

Martin Ratio

TAK:

-0.18

XLI:

6.86

Ulcer Index

TAK:

7.35%

XLI:

2.98%

Daily Std Dev

TAK:

17.49%

XLI:

13.68%

Max Drawdown

TAK:

-52.76%

XLI:

-62.26%

Current Drawdown

TAK:

-39.27%

XLI:

-3.99%

Returns By Period

In the year-to-date period, TAK achieves a 2.27% return, which is significantly lower than XLI's 4.39% return. Over the past 10 years, TAK has underperformed XLI with an annualized return of -1.33%, while XLI has yielded a comparatively higher 11.22% annualized return.


TAK

YTD

2.27%

1M

3.36%

6M

-4.43%

1Y

-1.85%

5Y*

-2.96%

10Y*

-1.33%

XLI

YTD

4.39%

1M

1.67%

6M

9.23%

1Y

17.57%

5Y*

12.07%

10Y*

11.22%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

TAK vs. XLI — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TAK
The Risk-Adjusted Performance Rank of TAK is 3737
Overall Rank
The Sharpe Ratio Rank of TAK is 4141
Sharpe Ratio Rank
The Sortino Ratio Rank of TAK is 3131
Sortino Ratio Rank
The Omega Ratio Rank of TAK is 3131
Omega Ratio Rank
The Calmar Ratio Rank of TAK is 4242
Calmar Ratio Rank
The Martin Ratio Rank of TAK is 4141
Martin Ratio Rank

XLI
The Risk-Adjusted Performance Rank of XLI is 6262
Overall Rank
The Sharpe Ratio Rank of XLI is 5959
Sharpe Ratio Rank
The Sortino Ratio Rank of XLI is 6262
Sortino Ratio Rank
The Omega Ratio Rank of XLI is 5858
Omega Ratio Rank
The Calmar Ratio Rank of XLI is 7070
Calmar Ratio Rank
The Martin Ratio Rank of XLI is 5959
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

TAK vs. XLI - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Takeda Pharmaceutical Company Limited (TAK) and Industrial Select Sector SPDR Fund (XLI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for TAK, currently valued at -0.07, compared to the broader market-2.000.002.004.00-0.071.49
The chart of Sortino ratio for TAK, currently valued at 0.02, compared to the broader market-6.00-4.00-2.000.002.004.006.000.022.21
The chart of Omega ratio for TAK, currently valued at 1.00, compared to the broader market0.501.001.502.001.001.26
The chart of Calmar ratio for TAK, currently valued at -0.03, compared to the broader market0.002.004.006.00-0.032.44
The chart of Martin ratio for TAK, currently valued at -0.18, compared to the broader market-10.000.0010.0020.0030.00-0.186.86
TAK
XLI

The current TAK Sharpe Ratio is -0.07, which is lower than the XLI Sharpe Ratio of 1.49. The chart below compares the historical Sharpe Ratios of TAK and XLI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00SeptemberOctoberNovemberDecember2025February
-0.07
1.49
TAK
XLI

Dividends

TAK vs. XLI - Dividend Comparison

TAK's dividend yield for the trailing twelve months is around 4.68%, more than XLI's 1.38% yield.


TTM20242023202220212020201920182017201620152014
TAK
Takeda Pharmaceutical Company Limited
4.68%4.78%4.41%3.69%5.80%3.84%4.94%8.33%5.14%6.91%5.34%5.03%
XLI
Industrial Select Sector SPDR Fund
1.38%1.44%1.63%1.64%1.25%1.55%1.94%2.15%1.77%2.07%2.15%1.85%

Drawdowns

TAK vs. XLI - Drawdown Comparison

The maximum TAK drawdown since its inception was -52.76%, smaller than the maximum XLI drawdown of -62.26%. Use the drawdown chart below to compare losses from any high point for TAK and XLI. For additional features, visit the drawdowns tool.


-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-39.27%
-3.99%
TAK
XLI

Volatility

TAK vs. XLI - Volatility Comparison

Takeda Pharmaceutical Company Limited (TAK) has a higher volatility of 6.62% compared to Industrial Select Sector SPDR Fund (XLI) at 3.79%. This indicates that TAK's price experiences larger fluctuations and is considered to be riskier than XLI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


3.00%4.00%5.00%6.00%7.00%SeptemberOctoberNovemberDecember2025February
6.62%
3.79%
TAK
XLI
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab